OmniAb, Inc.
Hugh (Heungnam) Kim has a diverse work experience in the field of scientific research and development. Hugh (Heungnam) currently holds the position of Senior Research Scientist at OmniAb, Inc. since February 2023. Prior to this, Hugh worked as a Senior Scientist II at 3T Biosciences from December 2021 to October 2022.
Before that, they served as a Senior Scientist at Gritstone Oncology from May 2019 to November 2021, and at Hengenix Biotech, Inc. from December 2017 to May 2019. Hugh also gained valuable experience as a Scientist at Roche Molecular Systems from January 2016 to July 2017, where they focused on the development of rabbit monoclonal antibodies for tissue diagnostics.
Furthermore, they served as a Senior Scientist at Biocare Medical LLC. from September 2012 to January 2016 and as a Basic Life Science Research Associate at Stanford University from November 2011 to September 2012.
Their career in research began at the National Institutes of Health/ NCI/Laboratory of Molecular Biology/Antibody Therapy Unit, where they held various roles including Research Fellow and Visiting Fellow from April 2003 to April 2011.
Overall, Hugh (Heungnam) Kim has accumulated extensive experience in the scientific research field, with expertise in antibody development and diagnostics.
Hugh (Heungnam) Kim obtained their Ph.D. in Environmental Health Science from the University of Occupational and Environmental Health Japan, where they studied from 1999 to 2003.
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.